Holen Sie sich die Stockscreener-App
26.41
0.42%
0.11
Schlusskurs vom Vortag:
$26.30
Offen:
$26.43
24-Stunden-Volumen:
698
Relative Volume:
0.24
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.26%
1M Leistung:
-6.27%
6M Leistung:
-3.76%
1J Leistung:
+15.57%
1-Tages-Spanne:
$26.36
$26.43
1-Wochen-Bereich:
$25.84
$26.43
52-Wochen-Spanne:
$22.90
$30.11
Tema Oncology Etf Stock (CANC) Company Profile
Firmenname
Tema Oncology Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CANC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CANC | 26.39 | 0 | 0 | 0 | 0 | 0.00 |
| VTI | 294.83 | 417.53B | 0 | 0 | 0 | 0.00 |
| SPY | 593.03 | 372.57B | 0 | 0 | 0 | 0.00 |
| IVV | 596.01 | 253.41B | 0 | 0 | 0 | 0.00 |
| VB | 253.81 | 160.59B | 0 | 0 | 0 | 0.00 |
| QQQ | 504.05 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Oncology Etf Aktie (CANC) Neueste Nachrichten
(CANC) Investment Analysis - Stock Traders Daily
Pacer Data and Digital Revolution ETF (TRFK) Institutional Ownership 2024 - MarketBeat
(CANC) Technical Pivots with Risk Controls - Stock Traders Daily
7 Best-Performing Biotech ETFs for November 2024 - NerdWallet
The 5 Best Biotech ETFs of 2024 - TradingView
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
(CANC) Trading Advice - Stock Traders Daily
Thrivent Financial for Lutherans Invests $8.62 Million in Tema Oncology ETF (NASDAQ:CANC) - Defense World
National Bankshares Cuts Lucero Energy (CVE:LOU) Price Target to C$0.75 - Defense World
(CANC) Technical Data - Stock Traders Daily
Tema Oncology ETF (NASDAQ:CANC) Short Interest Update - Defense World
Where are the Opportunities in (CANC) - Stock Traders Daily
Tema Oncology ETF (NASDAQ:CANC) Sees Large Decrease in Short Interest - Defense World
When the Price of (CANC) Talks, People Listen - Stock Traders Daily
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
Tema American Reshoring ETF: Benefiting From The Return Of U.S. Manufacturing - Seeking Alpha
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Quantisnow
5 Small-cap Biotech ETFs to Watch (Updated 2024) | INN - Investing News Network
Tema ETFs CIO on Investment Opportunities in Biotech - Opto RoW
9 Best Biotech ETFs for 2024 - MSN
How Big Pharma Is Taking A Page Out Of Novartis' Playbook - Investor's Business Daily
10 Best Performing Biotech ETFs in 2024 - Yahoo Finance
Investment Surge in Healthcare ETFs Amidst Weight-Loss Drug Revolution - The PiPa News
11 Best Biotech ETFs To Buy - Yahoo Finance
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance
Viking Therapeutics' weight-loss tablet shows promise in small study - ETHealthWorld
Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction? - Investor's Business Daily
Sanofi CEO under pressure to woo investors after spending shock - Reuters.com
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads - Markets Insider
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund - Reuters
12 Best Healthcare ETFs To Buy - Yahoo Finance
Investing in Oncology: A Biotech Revolution in Research, Diagnosis, and Treatment of Cancer - Nasdaq
Oncology Market's Huge Potential Puts These Stocks in Focus - Yahoo Finance
Royalties and cancer treatments: Thematic ETFs take new directions - InvestmentNews
How BlackRock’s Rick Rieder is steering his active fixed-income ETF as bond funds struggle - MarketWatch
This Week in ETFs: 2 Funds Launch From Tema - ETFdb.com
Tema Launches Two Innovative, Active ETF Thematic Strategies: Oncology & Global Royalties - Business Wire
Tema launches three innovative, professionally managed thematic ETFs: American Reshoring, Luxury, & Monopolies and Oligopolies - Business Wire
Tema, Backed by Index, Accel and Zinal, Expands Access to Innovative Investment Themes Through Launch of Active ETF Platform - Business Wire
Ukroboronprom to Repair Captured Russian Tanks for Use by Ukrainian Army - Defense World
Pyxis Oncology (PYXS) Stock Price, News & Analysis - MarketBeat
Getting in on global luxury - ETF Strategy
Terns Pharmaceuticals (TERN) Stock Price, News & Analysis - MarketBeat
Relay Therapeutics (RLAY) Stock Price, News & Analysis - MarketBeat
Genmab A/S (GMAB) Stock Price, News & Analysis - MarketBeat
Arvinas (ARVN) Stock Price, News & AnalysisNASDAQ - MarketBeat
Cogent Biosciences (COGT) Stock Price, News & Analysis - MarketBeat
Exelixis (EXEL) Stock Price, News & AnalysisNASDAQ - MarketBeat
Finanzdaten der Tema Oncology Etf-Aktie (CANC)
Es liegen keine Finanzdaten für Tema Oncology Etf (CANC) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
0.21%
Kapitalisierung:
|
Volumen (24h):